| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Karolina Anderle, Michael Wolzt, Gabriele Moser, Bettina Keip, Johannes Peter, Claudia Meisslitzer, Ghazaleh Gouya, Michael Freissmuth and Cornelius Tschegg |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michael Wolzt, MD, Professor, Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria. michael.wolzt@meduniwien.ac.at |
| Key Words |
Irritable bowel syndrome; Diarrhea; Functional gastrointestinal disorder; Clinoptilolite; Zeolite; Treatment |
| Core Tip |
The purified clinoptilolite-tuff (PCT) product, G-PUR®, provided improvement in abdominal symptoms and stool abnormalities in patients with irritable bowel syndrome (IBS) with predominant diarrhea. Additionally, it reduced the use of rescue medication and tended to enrich gut microbiome diversity compared to placebo, while showing no safety concerns. Hence, the PCT product, G-PUR®, represents a promising novel treatment option for patients with IBS with predominant diarrhea. |
| Publish Date |
2022-12-08 09:04 |
| Citation |
Anderle K, Wolzt M, Moser G, Keip B, Peter J, Meisslitzer C, Gouya G, Freissmuth M, Tschegg C. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial. World J Gastroenterol 2022; 28(46): 6573-6588 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i46/6573.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i46.6573 |
